Local Access10 min readApril 9, 2026

    Buy Compounded Semaglutide in Denver: Telehealth vs Local Clinics (2026)

    Denver's health-forward reputation doesn't mean local GLP-1 clinic prices are affordable. In-person programs on the Front Range run $300–600/month for the same compounded semaglutide TRIMI delivers to any Denver address for $99/month.

    Why Denver Residents Choose Telehealth for GLP-1

    Denver has one of the most physically active populations of any American city, but this reputation can obscure the reality: Colorado's adult obesity rate is approximately 26%, and the Denver metro has seen significant growth in obesity-related conditions as the city has grown rapidly. Neighborhoods like Aurora, Commerce City, and southwest Denver have obesity and diabetes rates that far exceed the city's affluent reputation would suggest.

    At the same time, Denver's cost of living has increased dramatically over the past decade. Housing costs, transportation, and healthcare all compete for budget space — and for the roughly 12% of Denver metro adults without health insurance, brand-name GLP-1 medications at over $1,000/month are completely inaccessible. Even clinic-priced compounded semaglutide at $300–600/month is a significant burden. TRIMI's telehealth model at $99/month was designed to solve exactly this problem.

    Denver GLP-1 Snapshot

    Population: ~715,000 city / ~2.9 million metro. Colorado obesity rate: ~26%. Denver metro uninsured rate: ~12%. Typical clinic rate: $300–600/mo. Brand Wegovy: $1,000–$1,400/mo. TRIMI telehealth: $99/mo semaglutide, $125/mo tirzepatide.

    Colorado's telehealth laws are among the most permissive in the country. The state has consistently expanded telehealth coverage and removed geographic restrictions, making it straightforward for licensed Colorado providers to evaluate and prescribe GLP-1 medications for patients across the entire state — from Denver proper to the mountain towns and the rural Eastern Plains.

    Local Clinic vs. Telehealth: Pricing Comparison

    Cherry Creek and LoDo weight loss clinics — often catering to Denver's professional and tech-sector workforce — represent the upper end of local GLP-1 clinic pricing. But even more modest suburban practices in Aurora, Centennial, and Westminster charge $300+ per month when office visits are factored in.

    OptionMonthly CostIn-Person VisitInsurance Required
    Denver Weight Loss Clinic (avg)$300–$600YesSometimes
    Brand Wegovy (no insurance)$1,000–$1,400YesRecommended
    TRIMI Telehealth (compounded)$99/mo (sema) / $125/mo (tirz)NoNo

    How Telehealth Works: Consultation to Delivery in Denver

    Step 1: Online Health Intake

    Complete a secure health questionnaire from anywhere on the Front Range. Covers your medical history, current medications, BMI, and weight loss goals in about 10 minutes.

    Step 2: Colorado Provider Review

    A licensed Colorado provider reviews your intake, assesses GLP-1 candidacy, and creates a starting dose plan tailored to your health profile — typically within 24–48 hours.

    Step 3: Prescription to Pharmacy

    Prescription sent to a licensed compounding pharmacy. Flat pricing: $99/mo for semaglutide or $125/mo for tirzepatide. No insurance, no prior authorization, no hidden fees.

    Step 4: Delivered to Your Front Range Door

    Medication arrives at your Denver, Aurora, or suburban Front Range address within 3–5 business days. Ongoing care and adjustments handled through the TRIMI platform.

    Available Medications

    Compounded Semaglutide

    $99/month

    • Same active ingredient as Wegovy
    • Weekly self-injection
    • ~15% average weight loss at 68 weeks
    • No insurance required

    Compounded Tirzepatide

    $125/month

    • Dual GLP-1/GIP receptor agonist
    • Weekly self-injection
    • ~22% average weight loss at 72 weeks
    • No insurance required

    Compare your options in the semaglutide vs. tirzepatide guide, or learn more about what to look for in a GLP-1 telehealth provider.

    Getting Started with TRIMI in Denver

    Denver residents with a BMI of 27 or higher (with a weight-related condition) or 30 or higher can start the TRIMI process entirely online in about 10 minutes. No in-person appointment, no insurance paperwork, no prior authorization. Your first delivery ships to any Front Range address within 3–5 business days.

    Review whether you qualify for GLP-1 treatment and learn about how compounded medication safety is maintained at licensed compounding pharmacies.

    Ready to Start in Denver?

    Get compounded semaglutide delivered to any Denver or Front Range address for $99/month — no office visit, no insurance required.

    Get Started for $99/Month

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medications requiring evaluation by a licensed healthcare provider. Individual results vary. Common side effects include nausea, vomiting, diarrhea, and constipation. Not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. Colorado Department of Public Health and Environment. Obesity and Chronic Disease: BRFSS Data. 2023.
    5. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 9, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Compare San Jose GLP-1 clinic pricing to Trimi's $99/mo telehealth semaglutide.

    Compare Columbus GLP-1 clinic pricing to Trimi's $99/mo telehealth semaglutide.

    Start your GLP-1 journey — from $99/mo

    Get Started